Sebetralstat
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 33 publications
Evaluating deucrictibant for the treatment of hereditary angioedema.
Journal: Expert opinion on pharmacotherapy
Published: August 24, 2026
Current and future therapies for bradykinin-mediated angioedema
Journal: Dermatologie (Heidelberg, Germany)
Published: May 27, 2026
Diverse Trial Designs, Populations, and Outcomes: A Systematic Literature Review of Trials for the Treatment of Hereditary Angioedema Attacks.
Journal: Advances in therapy
Published: April 09, 2026
Comparative Efficacy of Recombinant C1 Inhibitor Versus Sebetralstat for On-Demand Treatment of Hereditary Angioedema Attacks: A Matching-Adjusted Indirect Treatment Comparison.
Journal: Advances in therapy
Published: March 05, 2026
Ekterly (sebetralstat) for hereditary angioedema: the first FDA-approved oral on-demand therapy.
Journal: Annals of medicine and surgery (2012)
Published: February 26, 2026
Isolated angioedema in the emergency department: rarely an allergic reaction.
Journal: The American journal of emergency medicine
Published: February 09, 2026
Sebetralstat (Ekterly) for treatment of hereditary angioedema attacks.
Journal: The Medical letter on drugs and therapeutics
Published: February 06, 2026
Sebetralstat for on-demand treatment of hereditary angioedema: A pooled analysis of placebo-controlled clinical trials.
Journal: The World Allergy Organization journal
Published: December 22, 2025
Sebetralstat for breakthrough attacks in patients with hereditary angioedema receiving long-term prophylaxis in KONFIDENT-S.
Journal: The journal of allergy and clinical immunology. Global
Published: December 01, 2025
Correction to "Sebetralstat (KVD900): A Potent and Selective Small Molecule Plasma Kallikrein Inhibitor Featuring a Novel P1 Group as a Potential Oral On-Demand Treatment for Hereditary Angioedema".
Journal: Journal of medicinal chemistry
Published: October 30, 2025
Sebetralstat: a paradigm shift in hereditary angioedema management.
Journal: Annals of medicine and surgery (2012)
Published: September 18, 2025
Sebetralstat as a patient-centered alternative to lanadelumab: Insights from recent real-world evidence.
Journal: Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
Published: August 25, 2025
Last Updated: 09/26/2026